logo-loader
viewShield Therapeutics PLC

Shield Therapeutics CEO hails positive head-to-head Feraccru study results

Carl Sterritt, chief executive of Shield Therapeutics PLC (LON:STX), tells Proactive London's Andrew Scott that Feraccru, its iron deficiency drug, has proved itself to be just as good as the current standard of care treatment in a late-stage trial.

The year-long phase IIIb study confirmed Feraccru’s “non-inferiority” to Ferinject when it came to boosting patients’ haemoglobin (Hb) levels.

As part of its commercialisation agreement with Norgine BV, Shield will now receive a €2.5mln milestone payment.

Quick facts: Shield Therapeutics PLC

Price: 190.5 GBX

LSE:STX
Market: LSE
Market Cap: £223.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics: Analyst discusses further positive data from...

Proactive Research analyst Emma Ulker discusses further positive data which has been released from Shield Therapeutics' (LON:STX) non-inferiority AEGIS H2H study. It pitted Shield's oral ferric maltol (branded as Feraccru in Europe and Accrufer in US) against intravenous ferric carboxymaltose...

on 31/10/19

2 min read